HAVCR2 and breast cancer: Indeed, it was recently shown that anti-Tim-3 blocking in combination with Paclitaxel administration amplified anti-tumor immune responses against breast cancer in vivo, and this inhibition was facilitated by the galectin-9-Tim-3 interaction, rather than the HMGB1-nucleic acid-Tim3 or PS-Tim3 interaction (148).